Purple Biotech (PPBT) Operating Expenses (2014 - 2026)

Purple Biotech (PPBT) has reported Operating Expenses for 12 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 5.1% year-over-year to $1.3 million in Q2 2026; TTM through Jun 2026 was $28.4 million, a 389.78% increase from a year earlier, with the FY2025 full-year figure at $27.5 million, up 149.5% from the prior year.
• Operating Expenses was $1.3 million for Q2 2026 at Purple Biotech, down from $2.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $23.4 million in Q4 2025 and troughed at $1.0 million in Q4 2024.
• A 5-year average of $4.8 million and a median of $4.0 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses plunged 83.79% in 2024 and soared 2207.68% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $6.6 million in 2022, then dropped by 5.06% to $6.3 million in 2023, then sank by 83.79% to $1.0 million in 2024, then soared by 2207.68% to $23.4 million in 2025, then plunged by 94.46% to $1.3 million in 2026.
• The last three Operating Expenses figures came in at $1.3 million (Q2 2026), $2.3 million (Q1 2026), and $23.4 million (Q4 2025), per Business Quant data.